Medunik USA reaffirms support for Sickle Cell Disease community with uninterrupted supply and Patient-Centered Services

PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...

(CNW) Medunik USA reaffirms support for Sickle Cell Disease community with uninterrupted supply and Patient-Centered Services

CNW/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik USA is ...

Micropores enhance organ-on-chip models for studying hidden infections

A new study provides a powerful way to study infections in environments that closely mimic human organs. The strategy, tested ...

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th – NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
eLife

Apparent cooperativity between human CMV virions introduces errors in conventional methods of calculating multiplicity of infection

Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

Thousands lose care as a result of NIH grant terminations

More than 74,000 participants in clinical trials lost their access to care as a result of Trump administration cuts, ...
eLife

The role of co-infection in the pathogenesis of acute SARS-CoV-2 infection and development of post-acute sequelae: A perspective

Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or ...
Managed Healthcare Executive

Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today ...

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic …

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
Medical Dialogues

Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3 trial

Gilead Sciences has announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who ...
Earth.com

Why are women hit harder by long COVID? New clues emerge

Gut, immune, and hormone disruptions reveal why long COVID symptoms can be more intense and long lasting in many women.